A Phase 3 interventional study of adalimumab and placebo in Crohn's Disease, sponsored by Abbott. Completed at 21 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-11.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 23rd largest by enrollment, is one of 3 that started in 2006, is one of 22 in phase 3, and was the 7th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
17 studies in Crohn Disease by Abbott: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 17 studies in Crohn Disease by Abbott, this one is the 13th largest by enrollment, is one of 3 that started in 2006, is one of 10 in phase 3, and was the 10th registered.
Abbott’s Crohn Disease studies by the year they started, since 2002.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 17 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
Biological: adalimumab · Biological: placebo
Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
Biological: adalimumab
At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
Also known as: ABT-D2E7, Humira
At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
Also known as: ABT-D2E7, Humira
Number of Subjects Without Mucosal Ulceration at Week 12
Subjects were to have undergone up to 4 endoscopies to evaluate the presence or absence of mucosal ulceration: at Screening, at Week 12 (subjects who moved to open label (OL) drug between Week 8 and Week 12 because of disease flare or non-response were evaluated by endoscopy prior to receiving OL dosing), at the time of switch from blinded study drug to OL adalimumab at any time after Week 12, and at Week 52 or Early Termination. Subjects who remained blinded for the entire 52-week trial or switched to OL adalimumab between Week 8 and Week 12 were to have undergone 3 endoscopies.
Time frame: Week 12
Number of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) < 150 at Week 12
Clinical remission is defined as a CDAI less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.
Time frame: Week 12
Number of Subjects Without Mucosal Ulceration at Week 52
The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at Week 52.
Time frame: Week 52
Number of Subjects With Clinical Remission (CDAI < 150) at Week 52
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.
Time frame: Week 52
Number of Subjects Without Mucosal Ulceration at Both Week 12 and Week 52
The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at both Week 12 and Week 52.
Time frame: Weeks 12 and 52
Number of Subjects With Clinical Remission (CDAI < 150) at Both Week 12 and Week 52
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.
Time frame: Weeks 12 and 52
Subjects were to be enrolled in 9 countries. Subjects were enrolled at 19 sites in 8 countries. No subjects were enrolled in Sweden.
| Milestone | Placebo | Adalimumab |
|---|---|---|
| Started | 0 | 135 |
| Completed | 0 | 129 |
| Not completed | 0 | 6 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Protocol violation | 0 | 4 |
| Milestone | Placebo | Adalimumab |
|---|---|---|
| Started | 65 | 64 |
| Completed | 60 | 54 |
| Not completed | 5 | 10 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Milestone | Placebo | Adalimumab |
|---|---|---|
| Started | 0 | 100 |
| Completed | 0 | 66 |
| Not completed | 0 | 34 |
| Withdrew: Adverse event | 0 | 8 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 13 |
| Withdrew: Administrative reasons | 0 | 5 |
| Withdrew: Subject moved to the united states | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
Subjects were to have undergone up to 4 endoscopies to evaluate the presence or absence of mucosal ulceration: at Screening, at Week 12 (subjects who moved to open label (OL) drug between Week 8 and Week 12 because of disease flare or non-response were evaluated by endoscopy prior to receiving OL dosing), at the time of switch from blinded study drug to OL adalimumab at any time after Week 12, and at Week 52 or Early Termination. Subjects who remained blinded for the entire 52-week trial or switched to OL adalimumab between Week 8 and Week 12 were to have undergone 3 endoscopies.
| Subjects | Placebo | Adalimumab |
|---|---|---|
| Number of Subjects Without Mucosal Ulceration at Week 12 | 8 | 17 |
Clinical remission is defined as a CDAI less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.
| Subjects | Placebo | Adalimumab |
|---|---|---|
| Number of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) < 150 at Week 12 | 18 | 30 |
The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at Week 52.
| Subjects | Placebo | Adalimumab |
|---|---|---|
| Number of Subjects Without Mucosal Ulceration at Week 52 | 0 | 15 |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.
| Subjects | Placebo | Adalimumab |
|---|---|---|
| Number of Subjects With Clinical Remission (CDAI < 150) at Week 52 | 6 | 21 |
The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at both Week 12 and Week 52.
| Subjects | Placebo | Adalimumab |
|---|---|---|
| Number of Subjects Without Mucosal Ulceration at Both Week 12 and Week 52 | 0 | 7 |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.
| Subjects | Placebo | Adalimumab |
|---|---|---|
| Number of Subjects With Clinical Remission (CDAI < 150) at Both Week 12 and Week 52 | 3 | 19 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | — | 43/65 (66.2%) |
| Adalimumab | — | 20/135 (14.8%) | 49/64 (76.6%) |
| Event | Placebo | Adalimumab |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | — | 8/135 |
| Coronary artery diseaseCardiac disorders | — | 1/135 |
| Ileal stenosisGastrointestinal disorders | — | 1/135 |
| Intestinal fistulaGastrointestinal disorders | — | 1/135 |
| Type IV hypersensitivity reactionImmune system disorders | — | 1/135 |
| Anal abscessInfections and infestations | — | 1/135 |
| Herpes zosterInfections and infestations | — | 1/135 |
| Perianal abscessInfections and infestations | — | 1/135 |
| TonsillitisInfections and infestations | — | 1/135 |
| Vulval abscessInfections and infestations | — | 1/135 |
| Event | Placebo | Adalimumab |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 19/65 | 15/64 |
| NasopharyngitisInfections and infestations | 8/65 | 9/64 |
| HeadacheNervous system disorders | 6/65 | 9/64 |
| Abdominal painGastrointestinal disorders | 6/65 | 8/64 |
| FatigueGeneral disorders | 2/65 | 7/64 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/65 | 7/64 |
| Influenza like illnessGeneral disorders | 3/65 | 6/64 |
| FlatulenceGastrointestinal disorders | 1/65 | 5/64 |
| NauseaGastrointestinal disorders | 3/65 | 5/64 |
| Upper respiratory tract infectionInfections and infestations | 3/65 | 5/64 |
| Age, Categorical(Participants) | Placebo | Adalimumab 40 mg Every Other Week | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 63 | 62 | 125 |
| >=65 years | 1 | 1 | 2 |
| Age Continuous(years) | Placebo | Adalimumab 40 mg Every Other Week | Total |
|---|---|---|---|
| Mean | 37.2 ± 12.60 | 37.1 ± 11.10 | 37.1 ± 11.84 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab 40 mg Every Other Week | Total |
|---|---|---|---|
| Female | 41 | 40 | 81 |
| Male | 24 | 24 | 48 |
| Region of Enrollment(participants) | Placebo | Adalimumab 40 mg Every Other Week | Total |
|---|---|---|---|
| France | 3 | 3 | 6 |
| United States | 20 | 12 | 32 |
| Canada | 22 | 18 | 40 |
| Belgium | 14 | 25 | 39 |
| Austria | 2 | 0 | 2 |
| Netherlands | 1 | 2 | 3 |
| Germany | 1 | 1 | 2 |
| Italy | 2 | 3 | 5 |
The record gives a start of Aug 2006 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab